2026 Global: Cancer Biopsies Market-Competitive Review (2032) report
Description
The 2026 Global: Cancer Biopsies Market-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cancer biopsies market by geography and historical trend. The scope of the report extends to sizing of the cancer biopsies market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
QIAGEN N.V., Illumina, Inc., Guardant Health, F. Hoffmann-La Roche Ltd., and Thermo Fisher Scientific Inc. lead the cancer biopsies market, alongside BD, Myriad Genetics, Exact Sciences Corporation, Natera Inc., and ANGLE plc as the ten major players. These companies dominate through innovations in liquid biopsy technologies, next-generation sequencing (NGS), and circulating tumor DNA (ctDNA) analysis, capturing significant shares in a market projected to grow rapidly due to rising cancer prevalence and demand for non-invasive diagnostics. QIAGEN excels in sample preparation kits for ctDNA extraction, launching compatible products for QIAseq workflows in January 2025, while Illumina partners with Roche for NGS-based tools in oncology, enhancing multi-cancer profiling as of September 2024. Guardant Health secured FDA approval for its Guardant360 CDx in April 2025, enabling comprehensive solid tumor analysis from blood, and maintains a vertically integrated model across global regions. F. Hoffmann-La Roche integrates diagnostics with its global presence, driving liquid biopsy adoption via companion diagnostics, and ranks among top market leaders.
Myriad Genetics, Exact Sciences, Natera, BD (Becton Dickinson), and Biocept further solidify the top tier with specialized assays and services. Myriad provides precision medicine solutions for hereditary cancer risk and tumor profiling, consistently listed in leading rankings. Exact Sciences advances blood-based tests, acquiring stakes in Asian firms for colorectal and pancreatic cancer detection in March 2025, and offers multi-target stool DNA screening like Cologuard. Natera focuses on cell-free DNA tests for oncology via robust R&D and collaborations, holding top market positions. BD contributes through biopsy devices and liquid biopsy integration, while Biocept expands cerebrospinal fluid testing for CNS tumors in November 2024 and employs Target Selector technology for CTC and ctDNA capture across cancers. These firms leverage North America's advanced infrastructure, where reimbursement policies and NCI funding accelerate adoption.
Market dynamics favor these leaders amid technological shifts toward NGS and outsourced analytics, with North America commanding the largest share. Recent developments, including LabCorp's 2025 MRD platform and GRAIL's Galleri test for multi-cancer detection via cfDNA, underscore competitive intensity, though core players like the ten listed maintain dominance through FDA approvals, partnerships, and broad portfolios. ANGLE plc's Parsortix system for CTC isolation based on size complements tissue biopsy alternatives, reinforcing non-invasive trends. Overall, these companies drive revenue growth from USD 4-7 billion in 2025 toward USD 22 billion by 2034, fueled by precision oncology demands.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cancer biopsies market by geography and historical trend. The scope of the report extends to sizing of the cancer biopsies market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
QIAGEN N.V., Illumina, Inc., Guardant Health, F. Hoffmann-La Roche Ltd., and Thermo Fisher Scientific Inc. lead the cancer biopsies market, alongside BD, Myriad Genetics, Exact Sciences Corporation, Natera Inc., and ANGLE plc as the ten major players. These companies dominate through innovations in liquid biopsy technologies, next-generation sequencing (NGS), and circulating tumor DNA (ctDNA) analysis, capturing significant shares in a market projected to grow rapidly due to rising cancer prevalence and demand for non-invasive diagnostics. QIAGEN excels in sample preparation kits for ctDNA extraction, launching compatible products for QIAseq workflows in January 2025, while Illumina partners with Roche for NGS-based tools in oncology, enhancing multi-cancer profiling as of September 2024. Guardant Health secured FDA approval for its Guardant360 CDx in April 2025, enabling comprehensive solid tumor analysis from blood, and maintains a vertically integrated model across global regions. F. Hoffmann-La Roche integrates diagnostics with its global presence, driving liquid biopsy adoption via companion diagnostics, and ranks among top market leaders.
Myriad Genetics, Exact Sciences, Natera, BD (Becton Dickinson), and Biocept further solidify the top tier with specialized assays and services. Myriad provides precision medicine solutions for hereditary cancer risk and tumor profiling, consistently listed in leading rankings. Exact Sciences advances blood-based tests, acquiring stakes in Asian firms for colorectal and pancreatic cancer detection in March 2025, and offers multi-target stool DNA screening like Cologuard. Natera focuses on cell-free DNA tests for oncology via robust R&D and collaborations, holding top market positions. BD contributes through biopsy devices and liquid biopsy integration, while Biocept expands cerebrospinal fluid testing for CNS tumors in November 2024 and employs Target Selector technology for CTC and ctDNA capture across cancers. These firms leverage North America's advanced infrastructure, where reimbursement policies and NCI funding accelerate adoption.
Market dynamics favor these leaders amid technological shifts toward NGS and outsourced analytics, with North America commanding the largest share. Recent developments, including LabCorp's 2025 MRD platform and GRAIL's Galleri test for multi-cancer detection via cfDNA, underscore competitive intensity, though core players like the ten listed maintain dominance through FDA approvals, partnerships, and broad portfolios. ANGLE plc's Parsortix system for CTC isolation based on size complements tissue biopsy alternatives, reinforcing non-invasive trends. Overall, these companies drive revenue growth from USD 4-7 billion in 2025 toward USD 22 billion by 2034, fueled by precision oncology demands.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
